DUBLIN, March 28, 2022 /PRNewswire/ — The “Market forecasts for immuno-oncology diagnostics with COVID-19 impact and updates” Report has been added to ResearchAndMarkets.com offering.
Diagnostics, complementary diagnostics, are driving the success of Immuno-Oncology Therapeutics. A whole new segment of the diagnostics industry is being created and it is not a small segment either.
It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. An intricate web of pharmaceutical companies, diagnostic companies and instrumentation providers are vying for position in a new approach to conquering cancer. The approach appears to be working and showing great promise.
A revolution in cancer therapy is underway. New therapy based on the use of the body’s natural immune defenses is seeing unprecedented success, but diagnostics, especially biomarkers, are desperately needed to help select the appropriate therapy.
Technology advances faster than the market. The impact on the health care industry is huge. Tumor mutational burden? Checkpoint inhibitors? Cytokines?
Learn about the technology in easily understandable terms that explain the jargon. Find the opportunities and the traps. Understand the growth expectations and ultimate potential size of the market in this comprehensive new expanded report.
Key Topics Covered:
Cancer Immuno-Oncology Diagnosis Recent Advances
Lucence liquid biopsy test tracks changes in ctDNA from immune treatment
Qiagen and OncXerna Close Companion Dx Development Agreement
natera test to guide therapy for bladder cancer
Acquisition of Veracyte Halio to boost immuno-oncology activity
Freenome Eyes New Dx Possibilities
Oncocyte data have potential as a predictor of response to immunotherapy
OncoDNA uses HalioDx to expand to North America
Adaptive Biotechnologies, Q2 solutions agreement for the ImmunoSeq assay.
Qiagen Expands Its Immuno-Oncology Portfolio
Immune profile system redirected to fight COVID-19
PD-L1 Detection Patent Awarded to IncellDx
FDA approves CDx for trastuzumab
Promega Earns CE Mark for Microsatellite Instability IVD
ArcherDx partners with AstraZeneca for immuno-oncology
Germline results guide precision therapy
Agilent PD-L1 assay gains FDA approval
Bayer and OrigiMed Form Companion Diagnostics Development Alliance
Bio-Me to develop microbiome biomarker test for cancer immunotherapy
SkylineDx and BioInvent collaborate to characterize predictive immune signatures
Biocare Medical Launches 7 New IVD Antibodies
Oncocyte to acquire Insight Genetics for $12 million
Novigenix and BioLizard will develop a diagnostic algorithm based on NGS
Biodesix and Immodulon collaborate for the treatment of pancreatic cancer
Generex to merge with NuGenerex Immuno-Oncology
Cellgen Diagnostics and Genomic Testing Cooperative Partners to Develop Companion Diagnostics for Cancer Therapies
Hematogenix Launches FDA-Approved Immuno-Oncology Test for Triple Negative Breast Cancer
Icon Acquires MolecularMD
Factors that limit growth
Development of diagnostic technology
Combinations – Problems and Complexity
Changing role of diagnostics
Multiplexing and Foundation One
The disruptive dynamic
The race for biomarkers
the next five years
Immunotherapy – Immune Technologies Guide
innate immune system
natural killer cells
adaptive immune system
Genomic germ line
Key Immuno-Oncology Company Profiles
10x Genomics, Inc.
Agena Bioscience, Inc.
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnosis
Becton, Dickinson and Company
BGI Genomics Co. Ltd.
Bio-Rad Laboratories, Inc.
Caris Molecular Diagnosis
castle biosciences, inc.
CellMax Shelf Life
Charles River Laboratories
Cytolumina Technologies Corp.
Datar Cancer Genetics Limited
FUJIFILM Your Diagnosis
discovery of the horizon
HTG Molecular Diagnostics
MDNA Life Sciences, Inc.
Menarini Silicon Biosystems
Myriad Genetics/Myriad RBM
Novogene Bioinformatics Technology Co., Ltd.
Ortho Clinical Diagnosis
Oxford Nanopore Technologies
Personal Genome Diagnosis
Roche Molecular Diagnostics
Singlera Genomics Inc.
Time Laboratories, Inc.
ThermoFisher Scientific Inc.
Thrive early detection
For more information on this report, visit https://www.researchandmarkets.com/r/p4t8zu
Research and Markets
laura woodSenior manager
For business hours EST call +1-917-300-0470
For US/Canada call toll free +1-800-526-8630
For GMT business hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
See original content:https://www.prnewswire.com/news-releases/global-immuno-oncology-diagnostics-markets-2022-2027-outcome-potential-companion-diagnostics-funding-technology-environment–target-solutions-driving-growth -301511851.html
SOURCE Research and Markets